FINWIRES · TerminalLIVE
FINWIRES

$RVMD

15 stories mentioning RVMD

Every FINWIRES story that references RVMD, newest first.

Wire

Revolution Medicines' Cancer Drug Darax Seen Holding Lead Over Rivals, RBC Says

Revolution Medicines' (RVMD) cancer drug daraxonrasib is likely to keep its lead over emerging competitors, as some investors may be overstating the ability of rival treatments to match its performance, RBC Capital Markets said Tuesday in a report.RBC said its analysis suggests competing drugs are unlikely to show meaningful differences from daraxonrasib, setting a high bar ahead of upcoming data in pancreatic and lung cancer. Additional results in both diseases are expected to "converge on darax's profile," reinforcing its position, the report said.RBC said it would be a buyer of Revolution shares ahead of clinical updates from other companies, arguing that more data should highlight daraxonrasib's advantages and ease concerns about competition.Because daraxonrasib is expected to play a major role in treating pancreatic cancer, a rival drug would need to be clearly better and show a different safety and efficacy profile to take meaningful market share, the report said.RBC raised its price target on Revolution stock to $182 from $165 with a rating of outperform, speculative risk.Price: $155.68, Change: $-8.00, Percent Change: -4.89%

$RVMD
Wire

Revolution Medicines' Trial Data Shows Daraxonrasib is 'Winner' in Pancreatic Cancer Treatment, RBC Says

Revolution Medicines' (RVMD) full results from its RASolute-302 trial presented at a medical conference indicate that daraxonrasib is emerging as the "clear winner" for the second line treatment of pancreatic cancer, RBC Capital Markets said in a note Monday.The trial is an "inflection point" in second line pancreatic cancer treatment and for Revolution it "represents a large commercial opportunity," the note said.There is now a "clear near-term regulatory path" as well as optionality to bring the drug into other indications, for a potential opportunity of more than $10 billion, RBC said.The investment firm added that while the competitive landscape is intensifying, Revolution's new data sets a "high bar" and Revolution will likely stay the leader in the space.RBC has an outperform rating on Revolution and a $165 price target.Price: $159.93, Change: $+2.45, Percent Change: +1.56%

$RVMD
Wire

Revolution Medicines Says Phase 3 Daraxonrasib Trial Shows Survival Benefit in Metastatic Pancreatic Cancer

Revolution Medicines' (RVMD) phase 3 data for daraxonrasib showed improved overall survival and progression-free survival compared with chemotherapy in previously treated metastatic pancreatic cancer, the company said late Sunday.The phase 3 trial met all primary and key secondary endpoints, with daraxonrasib reducing the risk of death by 60% and increasing median overall survival to 13.2 months from about 6.6 months with chemotherapy, Revolution Medicines said.The once-daily oral therapy was generally well tolerated with a manageable safety profile, the company said.Revolution Medicines said it plans to submit data from the trial as part of its new drug application to the US Food and Drug Administration.Shares of Revolution Medicines were up over 10% in Monday premarket trading.Price: $174.50, Change: $+17.02, Percent Change: +10.81%

$RVMD
Research

Bernstein Initiates Revolution Medicines at Market Perform

Revolution Medicines (RVMD) has an average rating of buy and mean price target of $182.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$RVMD
Wire

RBC Capital Adjusts Revolution Medicines Price Target to $165 From $162, Maintains Outperform Speculative Risk Rating

RBC Capital Adjusts Revolution Medicines Price Target to $165 From $162, Maintains Outperform Speculative Risk Rating

$RVMD
Wire

Revolution Medicines Gets FDA Expanded Access Permit for Experimental Pancreatic Cancer Drug

Revolution Medicines (RVMD) received a "safe to proceed" letter from the US Food and Drug Administration, allowing to the company to initiate an expanded access treatment protocol for its experimental pancreatic cancer drug, daraxonrasib, the FDA said Friday.The expanded access is for patients with previously treated metastatic pancreatic ductal adenocarcinoma, the federal agency said.Shares of the company were down 2.3% in Friday trading.Price: $140.89, Change: $-3.24, Percent Change: -2.24%

$RVMD
Insider Trading

Revolution Medicines Insider Sold Shares Worth $413,129, According to a Recent SEC Filing

Anthony Mancini, Chief Global Commercialization Officer, on April 27, 2026, sold 3,120 shares in Revolution Medicines (RVMD) for $413,129. Following the Form 4 filing with the SEC, Mancini has control over a total of 54,400 common shares of the company, with 54,400 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1628171/000161071726000158/xslF345X05/form4.xml

$RVMD
Wire

UBS Adjusts Price Target on Revolution Medicines to $175 From $145, Maintains Buy Rating

Revolution Medicines (RVMD) has an average rating of buy and mean price target of $165.60, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $149.80, Change: $+1.16, Percent Change: +0.78%

$RVMD
Insider Trading

Revolution Medicines Insider Sold Shares Worth $18,010,488, According to a Recent SEC Filing

Mark A Goldsmith, Director, President and Chief Executive Officer, on April 15, 2026, sold 120,000 shares in Revolution Medicines (RVMD) for $18,010,488. Following the Form 4 filing with the SEC, Goldsmith has control over a total of 999,606 common shares of the company, with 276,698 shares held directly and 722,908 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1628171/000161071726000146/xslF345X05/form4.xml

$RVMD
Wire

Revolution Medicines Facing Further Upside After Daraxonrasib's Results, RBC Says

Revolution Medicines (RVMD) has several paths toward additional upside on potential M&A deals and a launch following the release of phase 3 data on its experimental anti-cancer drug daraxonrasib, RBC Capital Markets said in a note Monday.The investment firm said that Revolution "had always been planning for success," with no immediate changes to the company's pipeline or plans expected. The company is preparing for commercialization and continues to have high confidence in its clinical programs, according to the note.Given Revolution's "history of moving quickly and efficiently," the investment firm said it expects a potential launch in H2 with no regulatory or operational challenges.The release of the trial results may also place Revolution "back into takeout baskets" following unconfirmed media reports this year of AbbVie (ABBV) and Merck's (MRK) potential interest in the company, RBC said.RBC has an outperform rating on Revolution and lifted the company's price target to $162 from $140.Price: $143.00, Change: $+6.70, Percent Change: +4.92%

$RVMD
Wire

Revolution Medicines Plans Common Stock, Senior Notes Offerings

Revolution Medicines (RVMD) said late Monday it plans to offer $750 million of common stock and $250 million aggregate principal amount of convertible senior notes due 2033 in separate public offerings, subject to market and other conditions.The company expects to grant the underwriters a 30-day option to buy up to an additional $112.5 million of common stock and up to an additional $37.5 million principal amount of notes to cover over-allotments.Revolution Medicines said it plans to use net proceeds from both offerings for general corporate purposes.

$RVMD
Sectors

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) climbed 1.6%.In corporate news, Seer (SEER) shares jumped 12% after it confirmed Monday that it has received a non-binding and unsolicited offer from its shareholder Radoff-JEC Group to acquire all its outstanding Class A shares for $2.25 per share in cash plus a contingent value right.Revolution Medicines (RVMD) shares surged 40% after it said Monday the phase 3 trial of its experimental drug daraxonrasib to treat a type of pancreatic cancer met key goals.Spyre Therapeutics (SYRE) shares jumped 23% after the company said its SPY001 investigational treatment for moderate-to-severely active ulcerative colitis met its primary and key secondary endpoints in a phase 2 trial.Replimune (REPL) is facing "significant risk" related to its ongoing phase 3 trial of RP1 in melanoma after the US Food and Drug Administration rejected the company's biologics license application for the product candidate, Wedbush Securities said in a note. Wedbush downgraded its rating on Replimune to neutral from outperform, with a lower price target of $2 from $19. Replimune shares tumbled 63%.

$REPL$RVMD$SEER$SYRE
Sectors

Sector Update: Health Care Stocks Softer Monday Afternoon

Health care stocks declined Monday afternoon, with the NYSE Health Care Index down 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.3%.The iShares Biotechnology ETF (IBB) added 0.8%.In corporate news, Replimune (REPL) is facing "significant risk" related to its ongoing phase 3 trial of RP1 in melanoma after the US Food and Drug Administration rejected the company's biologics license application for the product candidate, Wedbush Securities said in a note. Wedbush downgraded its rating on Replimune to neutral from outperform, with a lower price target of $2 from $19. Replimune shares tumbled 64%.Seer (SEER) shares jumped 12%. The company has received a non-binding proposal from the Radoff-JEC Group to acquire the company for $2.25 per share in cash plus a contingent value right, the latter said.Revolution Medicines (RVMD) shares surged 39% after it said Monday the phase 3 trial of its experimental drug daraxonrasib to treat a type of pancreatic cancer met key goals.Spyre Therapeutics (SYRE) shares jumped 28% after the company said its SPY001 investigational treatment for moderate-to-severely active ulcerative colitis met its primary and key secondary endpoints in a phase 2 trial.

$REPL$RVMD$SEER$SYRE
Wire

Top Midday Stories: Goldman Shares Fall Despite Q1 Earnings Topping Estimates; Revolution's Pancreatic Cancer Drug Met Key Study Goals

The Dow Jones Industrial Average was down while the S&P 500 and Nasdaq Composite were up in late-morning trading Monday, as Wall Street digests news from the weekend that the US and Iran failed to strike a deal, and President Donald Trump announced a blockade of the Strait of Hormuz.In company news, Goldman Sachs (GS) reported Q1 earnings Monday of $17.55 per diluted share, up from $14.12 a year earlier and above the FactSet consensus analyst estimate of $16.47. First-quarter net revenue was $17.23 billion, up from $15.06 billion a year ago and above the FactSet consensus of $16.99 billion. The company also said it's launching a three-tranche, investment-grade bond offering in the US, with bond maturities spanning four to eight years, Bloomberg reported, citing a person with direct knowledge of the matter. Goldman shares were down 3.6% around midday.Revolution Medicines (RVMD) said Monday the phase 3 trial of its experimental drug, daraxonrasib, intended to treat a type of pancreatic cancer, met key goals. The drug delivered a median overall survival of 13.2 months, compared with 6.7 months for chemotherapy, the company said. Revolution said it plans to submit the data to global regulators, including the US Food and Drug Administration, for marketing application. Revolution shares were up 36.4%.GFL Environmental (GFL) has entered into a definitive agreement to acquire all of the issued and outstanding shares of Secure Waste Infrastructure for 24.75 Canadian dollars per share, representing an enterprise value of about CA$6.4 billion ($4.62 billion), the companies said Monday. The deal is expected to close in H2, they said. GFL shares were down 7.8%.Fastenal (FAST) reported Q1 earnings Monday of $0.30 per diluted share, up from $0.26 a year earlier and in-line with the FactSet consensus. First-quarter net sales were $2.20 billion, up from $1.96 billion a year ago and in-line with expectations. Fastenal shares were down 6.7%.Conagra Brands (CAG) said Monday it has appointed John Brase as chief executive officer and president, effective June 1. Brase, who previously served as chief operating officer and president at J.M. Smucker (SJM), will succeed Sean Connolly, who will step away from his leadership positions and board seat on May 31, the company said. Conagra shares were down 5.6%, while J.M. Smucker shares were down 2.7%.Microsoft (MSFT) is developing new features for Copilot it hopes will make the AI assistant function more like OpenClaw, The Information reported Monday, citing a company statement. Microsoft shares were up 2.3%.Price: $874.99, Change: $-32.81, Percent Change: -3.61%

$CAG$FAST$GFL$GS$MSFT$RVMD$SJM
Wire

Revolution Medicines' Drug Shows Survival Benefit in Pancreatic Cancer Trial; Shares Rise Pre-Bell

Revolution Medicines (RVMD) said Monday the phase 3 trial of its experimental drug, daraxonrasib, to treat a type of pancreatic cancer met key goals, showing significant improvements in progression-free and overall survival versus standard chemotherapy.The company said the drug delivered a median overall survival of 13.2 months, compared with 6.7 months for chemotherapy.The drug developer said it plans to submit the data to global regulators, including the US Food and Drug Administration, for marketing application.Shares of the company were up over 34% in Monday's premarket activity.Price: $129.87, Change: $+33.10, Percent Change: +34.32%

$RVMD